Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: An observational study from the Swedish National Diabetes Register

BMJ Open

Volumn 3, Issue 4, 2013, Pages

  Ekström, Nils ^a   Cederholm, Jan ^b   Zethelius, Björn ^c   Eliasson, Björn ^a   Fhärm, Eva ^d   Rolandsson, Olov ^d   Miftaraj, Mervete ^e   Svensson, Ann Marie ^e   Gudbjörnsdottir, Soffia ^a,e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e Center of Registers in Region Vastra Gotaland   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; INSULIN TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; SWEDEN;

EID: 84877684705     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002688     Document Type: Article

References (30)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy -I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
2. Antiplatelet Trialists' Collaboration. Collaborative meta-Analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
3. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
4. Siller-Matula JM. Hemorrhagic complications associated with aspirin: An underestimated hazard in clinical practice? JAMA 2012;307: 2318-20.
5. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395-402.
6. Perk J, De Backer G, Gohlke H, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of Nine Societies and by Invited Experts). Int J Behav Med 2012;19:40-88.
7. American Diabetes Association. Executive summary: standards of medical care in diabetes-2013. Diabetes Care 2013;36(Suppl 1): S4-10.
8. Cederholm J, Zethelius B, Nilsson PM, et al. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract [Research Support, Non-US Gov't]. 2009;86:74-81.
9. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). J Intern Med [Research Support, Non-U.S. Gov't]. 2010;268:471-82.
10. Gudbjornsdottir S, Eliasson B, Eeg-Olofsson K, et al. Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register. Diabetologia [Research Support, Non-US Gov't] 2011;54:2544-51.
11. Cederholm J, Gudbjornsdottir S, Eliasson B, et al. Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP II). J Hypertens 2012;30:2020-30.
12. Eliasson B, Cederholm J, Eeg-Olofsson K, et al. Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: A report from the Swedish National Diabetes Register. Diabetes Care [Research Support, Non-U.S. Gov't] 2011;34:2095-100.
13. Zethelius B, Eliasson B, Eeg-Olofsson K, et al. A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract 2011;93:276-84.
14. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register -opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35. (Pubitemid 47180362)
15. Merlo J, Lindblad U, Pessah-Rasmussen H, et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol [Comparative Study Research Support, Non-U.S. Gov't] 2000;16:235-43. (Pubitemid 30351427)
16. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1994;90: 583-612.
17. Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: A method-comparison study. Clin Chem [Comparative Study Multicenter Study Research Support, Non-US Gov't] 2004;50:166-74. (Pubitemid 38125714)
18. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med [Comparative Study] 1998;17:2265-81. (Pubitemid 28466823)
19. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998;54:948-63. (Pubitemid 28429289)
20. Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: A systematic review and meta-Analysis comparing patients with and without diabetes. Diabetes Care 2009;32:2300-6.
21. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-Analysis of randomised controlled trials. BMJ [Meta-Analysis Review] 2009;339:b4531.
22. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-Analysis. Diabetes Res Clin Pract 2010;87:211-18.
23. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268:1292-300.
24. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.
25. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008; 300:2134-41.
26. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
27. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-Analysis of randomized controlled trials. JAMA 2006;295:306-13.
28. De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012;307:2286-94.
29. Berger JS, Lala A, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-Analysis of randomized trials. Am Heart J 2011;162:115-24 e2.
30. Pulcinelli FM, Biasucci LM, Riondino S, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 2009;30:1279-86.